Showing 4261-4270 of 4952 results for "".
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- EZDERM Partners With Healthmonix to Provide Integrated MIPS Reporting for Dermatologistshttps://practicaldermatology.com/news/ezderm-partners-with-healthmonix-to-provide-integrated-mips-reporting-for-dermatologists/2458337/EZDERM, LLC and Healthmonix have partnered to integrate the MIPSPRO platform into the EZDERM suite of dermatology software solutions, including the integrated EZDERM Electronic Health Record and Practice Management systems. This partnership gives EZDERM clients access to education,
- Melanoma Incidence, Mortality On The Risehttps://practicaldermatology.com/news/melanoma-incidence-mortality-on-the-rise/2458339/Melanoma incidence and mortality is on the rise, according to a research letter published online by JAMA Dermatology. An estimated 76,380 Americans will be diagnosed with melanoma in 2016, and
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- PuraCap Rolls Out Two New Acne Productshttps://practicaldermatology.com/news/puracap-rolls-out-two-new-acne-products/2458351/PuraCap Pharmaceutical LLC is rolling out two new acne products, Eptex Controlled Release Acne Wash and Eptex Controlled Release Acne Relief Lotion. Available through healthcare professionals, the products utilize a controlled release Intelli-Tar
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Novan: Significant Improvement of Genital Warts with SB206https://practicaldermatology.com/news/novan-significant-improvement-of-genital-warts-with-sb206/2458355/Top-line results from Novan Inc.’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV show statistically significant benefits, the company reports. The highest dose tested, SB206 12%, demonstrated a st
- 8th Annual CSF Meeting Kicks Offhttps://practicaldermatology.com/news/8th-annual-csf-meeting-kicks-off/2458356/The Cosmetic Surgery Forum (CSF), now in its eighth year, was founded by NE-based dermatologist Joel Schlessinger, MD. CSF is a three-day multi-specialty educational symposium that covers the latest research, treatment and techniques in dermatology and cosmetic surgery. Unlike other meetings, res
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con